Jundishapur Journal of Microbiology

Published by: Kowsar

Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia

Pedram Haddadi 1 , Soheila Zareifar 2 , Parisa Badiee 3 , * , Abdolvahab Alborzi 3 , Maral Mokhtari 2 , Kamiar Zomorodian 4 , Keyvan Pakshir 4 and Hadis Jafarian 3
Authors Information
1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2014, 7 (9); e11858
  • Published Online: September 1, 2014
  • Article Type: Research Article
  • Received: May 1, 2013
  • Revised: August 10, 2013
  • Accepted: November 19, 2013
  • DOI: 10.5812/jjm.11858

To Cite: Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, et al. Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia, Jundishapur J Microbiol. 2014 ; 7(9):e11858. doi: 10.5812/jjm.11858.

Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. Mycoses. 2008; 51(3): 248-57[DOI][PubMed]
  • 2. Badiee P, Kordbacheh P, Alborzi A, Zakernia M, Haddadi P. Early detection of systemic candidiasis in the whole blood of patients with hematologic malignancies. Jpn J Infect Dis. 2009; 62(1): 1-5[PubMed]
  • 3. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol. 2005; 26(6): 548-52[DOI][PubMed]
  • 4. Marodi L, Johnston RB, Jr. Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr. 2007; 19(6): 693-7[DOI][PubMed]
  • 5. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001; 20(12): 1119-24[PubMed]
  • 6. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001; 345(23): 1660-6[DOI][PubMed]
  • 7. Pammi M, Eddama O, Weisman LE. Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units. Cochrane Database Syst Rev. 2011; (11)[DOI][PubMed]
  • 8. Zomorodian K, Rahimi MJ, Pakshir K, Motamedi M, Ghiasi MR, Rezashah H. Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis. 2011; 3(4): 357-60[DOI][PubMed]
  • 9. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4(2)-26
  • 10. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol. 2011; 3(4): 183-8[PubMed]
  • 11. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006; 44(3): 760-3[DOI][PubMed]
  • 12. Clinical and Laboratory Standards Institute . M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeast. Clinical and Laboratory Standards Institute 2008;
  • 13. Blignaut E, Messer SA, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infec Dis. 2002; 44(2): 169-74
  • 14. Davey KG, Holmes AD, Johnson EM, Szekely A, Warnock DW. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol. 1998; 36(4): 926-30[PubMed]
  • 15. Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses. 2004; 47(5-6): 177-83[DOI][PubMed]
  • 16. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50(6): 2009-15[DOI][PubMed]
  • 17. Maa SH, Lee HL, Huang YC, Wu JH, Tsou TS, MacDonald K, et al. Incidence density and relative risk of nosocomial infection in Taiwan's Only Children's Hospital, 1999-2003. Infect Control Hosp Epidemiol. 2008; 29(8): 767-70[DOI][PubMed]
  • 18. Badiee P, Alborzi A, Joukar M. Molecular assay to detect nosocomial fungal infections in intensive care units. Eur J Intern Med. 2011; 22(6): 611-5[DOI][PubMed]
  • 19. Farmaki E, Evdoridou J, Pouliou T, Bibashi E, Panagopoulou P, Filioti J, et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol. 2007; 24(2): 127-35[DOI][PubMed]
  • 20. Lopes MM, Barros R, Peres I, Serelha M, Neto MT, Cabrita J, et al. Surveillance of nosocomial fungal infections in a Portuguese paediatric hospital: incidence and risk factors. J Med Mycol. 2006; 16(4): 212-9
  • 21. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010; 13(4): 282-7[PubMed]
  • 22. Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. East Mediterr Health J. 2011; 17(5): 425-30[PubMed]
  • 23. Bakir M, Cerikcioglu N, Barton R, Yagci A. Epidemiology of candidemia in a Turkish tertiary care hospital. APMIS. 2006; 114(9): 601-10[DOI][PubMed]
  • 24. Pasqualotto AC, Nedel WL, Machado TS, Severo LC. A 9-year study comparing risk factors and the outcome of paediatric and adults with nosocomial candidaemia. Mycopathologia. 2005; 160(2): 111-6[DOI][PubMed]
  • 25. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med. 2007; 33(7): 1272-83[DOI][PubMed]
  • 26. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991; 325(18): 1274-7[DOI][PubMed]
  • 27. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002; 2(9): 550-63[PubMed]
  • 28. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002; 2(2): 73-85[PubMed]
  • 29. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother. 2004; 48(3): 970-8[PubMed]
  • 30. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4): 662-78[DOI][PubMed]
  • 31. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004; 42(7): 3142-6[DOI][PubMed]
  • 32. Fidel PL, Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12(1): 80-96[PubMed]
  • 33. Zaoutis TE, Foraker E, McGowan KL, Mortensen J, Campos J, Walsh TJ, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis. 2005; 52(4): 295-8[DOI][PubMed]
  • 34. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006; 19(2): 130-9[PubMed]
  • 35. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001; 45(10): 2676-84[DOI][PubMed]
  • 36. Posteraro B, Sanguinetti M, Fiori B, La Sorda M, Spanu T, Sanglard D, et al. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother. 2006; 58(2): 458-61[DOI][PubMed]
  • 37. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002; 46(6): 1704-13[PubMed]
  • 38. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002; 46(6): 1723-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments